Y-mAbs Therapeutics Shares Rise 10% After Resubmitting Biologics License Application

By Chris Wack

Y-mAbs Therapeutics Inc. shares were up 10% to $13 after the company said it completed the resubmission of its Biologics License Application for I-omburtamab to the U.S. Food and Drug Administration.

Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.

The biopharmaceutical company said the omburtamab BLA is for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. The submission is based on the safety and efficacy results of the pivotal Phase 2 studies 101 and 03-133, which the company expects to publish later this year.

Researchers at Memorial Sloan Kettering Cancer Center developed omburtamab, which is exclusively licensed to Y-mAbs. As a result of this licensing arrangement, Memorial Sloan Kettering has institutional financial interests related to the compound.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

April 01, 2022 12:27 ET (16:27 GMT)

Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Mar 2024 to Apr 2024